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Antibiotics, Acne, and Upper Respiratory Tract Infections
Abstract
About two million people per year in the U.S have acne severe enough to require treatment with antibiotics.
Treatment frequently lasts for more than six months, prompting concerns about antibiotic resistance and
other possible consequences of long-term antibiotic use, such as increased susceptibility to infections. This
Issue Brief summarizes a large study that evaluates the risk for upper respiratory and urinary tract infections
among adolescents and young adults treated with antibiotics for acne.
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Antibiotics, Acne, and Upper Respiratory
Tract Infections
Editor’s note: About two million people per year in the U.S have acne severe
enough to require treatment with antibiotics.  Treatment frequently lasts for
more than six months, prompting concerns about antibiotic resistance and
other possible consequences of long-term antibiotic use, such as increased
susceptibility to infections.  This Issue Brief summarizes a large study that
evaluates the risk for upper respiratory and urinary tract infections among
adolescents and young adults treated with antibiotics for acne.
Despite concern about the ramifications of long-term antibiotic use, few
studies have been conducted on populations of patients who have actually
been exposed to antibiotics for long periods.  Acne represents a model of a
disease in which to study this issue, because long-term antibiotic use (greater
than six weeks) is standard and appropriate therapy.
• Topical and oral antibiotics are frequently used to treat acne. The most
common antibiotics prescribed are tetracyclines, erythromycin, and
clindamycin.
• Previously, Margolis and colleagues showed that antibiotic therapy for acne
increased the chances that a young adult will harbor group A streptococci,
an organism associated with pharyngitis (sore throat).  In a small study,
they found that nearly 35% of acne patients on antibiotic therapy had
group A strep in their upper airway, and nearly 85% of the organisms were
resistant to tetracylines.  In comparison, about 19% of acne patient not
using antibiotics had group A strep organisms, 20% of which were resistant
to tetracylines. However, these patients had no symptoms of a sore throat
or respiratory illness and so the clinical implications of these findings are
not clear.
Study tracks rate of
infections in patients with
acne
Acne patients using
antibiotics had twice the
risk of URI within a year
as non-antibiotic users
• The question remains whether long-term antibiotic use results in an
increase in upper respiratory tract infections (URIs).  The vast majority of
URIs are viral, not bacterial, although some researchers suspect that
antibiotics may indirectly increase an individual’s susceptibility to viral
infections.
To determine whether long-term antibiotic use for acne results in increased
risk for infections,  Margolis and colleagues used the General Practitioner
Research Database (GPRD), a large medical records database in the United
Kingdom, to identify a group of patients ages 15-35 who had been diagnosed
with acne between 1987 and 2001.
• The researchers classified acne patients as antibiotic users if the database
indicated use of oral or topical antibiotics for more than six weeks, and
classified all other acne patients as non-users. All patients were followed up
in the database for 12 months after being identified.
• The researchers compared the incidence of URIs (such as pharyngitis,
tonsilitis and laryngitis) in antibiotic users and non-users.  To test whether
more frequent diagnosis of URI might be linked to more frequent doctor
visits by users, they also compared the incidence of urinary tract infections
in each group. Urinary tract infections are not likely to be affected by the
topical antibiotics used to treat acne.
• As a further test of whether a URI diagnosis is related to the frequency of
office visits, the researchers tracked URIs in a similar group of patients
with hypertension rather than acne.  These patients also have frequent
office visits, but should be at no increased risk for URIs.
The analysis confirmed that acne patients on long-term antibiotics have more
upper respiratory tract infections, even after accounting for factors such as
age, sex, and frequency of office visits for acne.
• Of 118,496 individuals with acne, 84,977 (71.7%) received topical or oral
antibiotics for more than six weeks and 33,519 (28.3%) did not.  Almost
93% of patients on antibiotics used a combination of topical and oral
agents.
• Within the first year of observation, 18,281 (15.4%) of the patients with
acne had at least one URI.  Antibiotic users were twice as likely to be
diagnosed with a URI as non-users, a risk that was present whether the
patient used topical antibiotics, oral antibiotics, or both.
• As expected, there was no difference between antibiotic users and non-
users in the rate of urinary tract infections.
Long-term antibiotics may
have systemic effects
• Hypertensive patients and acne patients not on antibiotics had similar rates
of URIs, again suggesting that health care-seeking behavior did not explain
the higher rate of URI in acne antibiotic users.
The reasons that acne antibiotic users might be at increased risk for URI are
not clear.  As noted earlier, most URIs are caused by viruses, which are not
directly affected by antibiotics used to treat acne. The researchers pose a
number of possible explanations for an increased risk for URI in this
population, including:
• The frequency of URIs of bacterial origin may be higher than previous
suspected, especially in this age group.
• Some URIs could have multiple origins, in that having one organism
(bacteria or virus) may increase the chances of infection by another
organism. In this case, patients harboring group A strep might be more
vulnerable to URIs of viral origin.
• Long-term antibiotics could cause immune system changes that could lead
to increased susceptibility to certain viral infections.
This study documents, for the first time, that antibiotic use in acne is
associated with an increased risk of URI.  Prolonged use of antibiotics may
cause social harm related to cost and the development of antibiotic-resistant
organisms and may cause individual harm to patients receiving prolonged
courses of antibiotics.  Further studies are needed to confirm these findings,
and to determine the mechanisms for the increased risk.
• At this point, these findings do not warrant a change in clinical practice.  If
the risk for URIs is confirmed, patients and practitioners will need to
balance the risk of these infections with the benefits that patients with acne
receive from antibiotics.
• Further research is needed to address important clinical questions, such
whether the dosages of antibiotics are linked to the risk, number, or
severity of infections.
• This study underscores the message that antibiotics should be used only
when necessary, and for only as long as necessary.
• Acne patients, many of whom use a combination of topical and systemic
antibiotics for long periods, make ideal subjects for studies of the long-
term effects of antibiotics and bacterial drug resistance.
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